Akanda (AKAN) Liabilities and Shareholders Equity (2020 - 2025)
Akanda's (AKAN) quarterly Liabilities and Shareholders Equity came in at $6.2 million in Q4 2025, down 21.71% year-on-year from $7.9 million in Q4 2024, and little changed quarter-over-quarter from $6.2 million in Q2 2025.
Akanda (AKAN) Liabilities and Shareholders Equity (2020 - 2025) Analysis & Trends
Akanda's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $6.2 million for Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity fell 21.71% year-over-year to $6.2 million in Q4 2025; TTM through Dec 2025 was $30.3 million, a 52.09% decrease from a year earlier, with the FY2025 full-year figure at $6.2 million, down 21.71% from the prior year.
- Liabilities and Shareholders Equity was little changed at $6.2 million in Q4 2025 per AKAN's latest filing, from $6.2 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $43.5 million in Q2 2022 and bottomed at $6.2 million in Q4 2025.
- The 5-year median for Liabilities and Shareholders Equity is $8.8 million (2023), against an average of $18.5 million.
- Across the five-year window, Liabilities and Shareholders Equity jumped 384.67% in 2022 and slumped 77.33% in 2023, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $8.0 million in 2021, then soared by 384.67% to $39.0 million in 2022, then slumped by 77.33% to $8.8 million in 2023, then dropped by 10.47% to $7.9 million in 2024, then dropped by 21.71% to $6.2 million in 2025.
- Per Business Quant, the three latest AKAN Liabilities and Shareholders Equity figures stand at $6.2 million (Q4 2025), $6.2 million (Q2 2025), and $7.9 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.71 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 69.30 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Akanda | 556,353.85 | 556,353.85 | - | 6.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.20 Mn |
| Jun 30, 2025 | 6.22 Mn |
| Dec 31, 2024 | 7.91 Mn |
| Jun 30, 2024 | 9.97 Mn |
| Dec 31, 2023 | 8.84 Mn |
| Jun 30, 2023 | 36.51 Mn |
| Dec 31, 2022 | 39.00 Mn |
| Jun 30, 2022 | 43.48 Mn |
| Dec 31, 2021 | 8.05 Mn |
| Dec 31, 2020 | 4.27 Mn |